Clinical Trial Update: Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations [Phase 1, Phase 2]

View source ↗

Summary

Early-phase clinical update on TYRA-300 showing safety signals and preliminary anti-tumor activity in locally advanced or metastatic urothelial carcinoma with F…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urinary Tract Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• TYRA-300

Snippet

Sponsor: Tyra Biosciences, Inc | Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING